New research suggests Pfizer's COVID-19 vaccine can protect against a mutation found in the two more-contagious variants of the coronavirus that have erupted in Britain and South Africa.

The results are reassuring, albeit preliminary, and not surprising to scientists who didn't expect a single mutation to defeat the shots on which the world has pinned its hopes. But the study marks just the beginning of continual monitoring to make sure that all the vaccines being rolled out around the world continue to work as the coronavirus, like all viruses, evolves.

"There's no reason to think the vaccines won't work just as well on these strains," said Dr. Frederic Bushman of the University of Pennsylvania, who tracks how the virus mutates.

The mutated version circulating in Britain has also been detected in the U.S. and numerous other countries. That and the variant seen in South Africa are causing global concern because they appear to spread more easily—although how much more isn't yet known.

Bushman, who wasn't involved with the Pfizer study, cautioned that it tested just one vaccine against one worrisome mutation. But the other vaccines now being used in the West—Moderna's and AstraZeneca's—are undergoing similar testing, and he said he expects similar findings.

That's because all the vaccines so far are prompting recipients' bodies to make antibodies against multiple spots on the spike protein that coats the virus.

"A mutation will change one little place, but it's not going to disrupt binding to all of them," Bushman explained.

The new study looked at one modification to the spike protein that both variants share, called N501Y, that is believed responsible for the easier transmission. Pfizer teamed with researchers from the University of Texas Medical Branch in Galveston for laboratory tests to see if that mutation could thwart its vaccine.

They used blood samples from 20 people who received the vaccine, made by Pfizer and its German partner BioNTech, during a large trial of the shots. Antibodies from those recipients fended off the virus in lab dishes, according to the told The Associated Press this week that the coronavirus variants don't appear to block vaccine-induced antibodies but that testing needed to be sure is underway in the U.S. and elsewhere.

British scientists have likewise said the variant found in the U.K. -– which has become the dominant type in parts of England—still seems to be susceptible to vaccines.

But the variant first discovered in South Africa has an additional mutation that has scientists on edge, one named E484K. The Pfizer study found that the vaccine appeared to work against 15 additional possible virus mutations, but E484K wasn't among those tested. Dormitzer said it is next on the list.

South Africa has not started mass vaccinations.

If the virus eventually mutates enough that the vaccine needs adjusting—much like flu shots are adjusted most years—tweaking the recipe wouldn't be difficult for vaccines made with newer technologies.

Both the Pfizer-BioNTech and Moderna vaccines are made with a piece of the virus genetic code, simple to switch, although it's not clear what kind of additional testing regulators would require to make such a change.

Dormitzer said this is only the beginning of "ongoing monitoring of virus changes to see if any of them might impact on vaccine coverage."

But the coronavirus isn't changing as rapidly as other viruses such as flu or HIV, and its structure is more stable than the flu's, Bushman said, although that will need to be tracked.

"My guess is vaccination will stick longer and be more effective than it is for influenza," he said.

© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

—Lauran Neergaard